PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers
Descrição
Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers
Statin Toxicity Circulation Research
Muscle- and skeletal-related side-effects of statins: tip of the iceberg? - Johann Auer, Helmut Sinzinger, Barry Franklin, Robert Berent, 2016
Frontiers Cardiovascular Abnormalities in Juvenile Dermatomyositis: A Scoping Review for the Clinical Rheumatologists
Atherogenic dyslipidemia in Latin America: prevalence, causes and treatment. Consensus
Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations: Molecular Therapy
Full article: Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management
Muscle Toxicity of Drugs: When Drugs Turn Physiology into Pathophysiology
Dyslipidaemia in type 2 diabetes: cardiovascular risk assessment and management
Myopathy with statin–fibrate combination therapy: clinical considerations
The Detection, Evaluation, and Management of Dyslipidemia in Children and Adolescents: A Canadian Cardiovascular Society/Canadian Pediatric Cardiology Association Clinical Practice Update - Canadian Journal of Cardiology
de
por adulto (o preço varia de acordo com o tamanho do grupo)
/i.s3.glbimg.com/v1/AUTH_bc8228b6673f488aa253bbcb03c80ec5/internal_photos/bs/2021/V/p/O70XRMRCiOd719sZOKUw/gta-rp-o-que-e.jpg)
